Skip to main navigation Skip to search Skip to main content

Vochysiamides A and B: Two new bioactive carboxamides produced by the new species Diaporthe vochysiae

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Endophytic fungi have been considered a rich source for bioactive secondary metabolites with novel chemical structures. A high diverse group of endophytes, isolated from different medicinal plants, belongs to the genus Diaporthe. In a previously study performed by our group the crude extract of strain LGMF1583 showed considerable antibacterial activity mainly against Gram-negative bacteria. Based on ITS phylogeny analysis, strain LGMF1583 was identified as belonging to Diaporthe genus and may represent a new species. In the present study, we described the new species Diporthe vochysiae based on multilocus phylogeny analysis and morphological characteristics. The species name refers to the host, from which strain LGMF1583 was isolated, the medicinal plant Vochysia divergens. In view of the biotechnological potential of strain LGMF1583, we have also characterized the secondary metabolites produced by D. vochysiae. Chemical assessment of the D. vochysiae LGMF1583 revealed two new carboxamides, vochysiamides A (1) and B (2), in addition to the known metabolite, 2,5-dihydroxybenzyl alcohol (3). In the biological activity analysis, vochysiamide B (2) displayed considerable antibacterial activity against the Gram-negative bacterium Klebsiella pneumoniae (KPC), a producer of carbapenemases, MIC of 80 μg/mL. Carbapenemases are considered a major antimicrobial resistance threat, and infections caused by KPC have been considered a public health problem worldwide, and new compounds with activity against this bacterium are nowadays even more required.

Original languageEnglish
Article number104273
JournalFitoterapia
Volume138
DOIs
StatePublished - Oct 2019

Bibliographical note

Publisher Copyright:
© 2019

Funding

This work was supported by National Institutes of Health grant R24 OD21479 (to J.S.T.), the University of Kentucky College of Pharmacy , the University of Kentucky Markey Cancer Center and the National Center for Advancing Translational Sciences ( UL1TR001998 and UL1TR000117 ). Additional support came from NIH grants R01 CA91091 , R01 GM105977 and an Endowed University Professorship in Pharmacy to J.R. It was also supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico – Brazil grant 424738/2016-3 and CNPq309971/2016-0 to C.G., and CAPES -Brazil – scholarship to D.C.S. We thank the College of Pharmacy NMR Center (University of Kentucky) for NMR support.

FundersFunder number
Endowed University
University of Kentucky
National Institutes of Health (NIH)R01 GM105977, R01 CA91091
NIH Office of the DirectorR24OD021479
National Center for Advancing Translational Sciences (NCATS)UL1TR001998, UL1TR000117
University of Kentucky Markey Comprehensive Cancer Center
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Conselho Nacional de Desenvolvimento Científico e Tecnológico424738/2016-3, CNPq309971/2016-0

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Carbapenemases
    • Diaporthe genus
    • Medicinal plants
    • Secondary metabolites
    • Vochysia divergens

    ASJC Scopus subject areas

    • Pharmacology
    • Drug Discovery

    Fingerprint

    Dive into the research topics of 'Vochysiamides A and B: Two new bioactive carboxamides produced by the new species Diaporthe vochysiae'. Together they form a unique fingerprint.

    Cite this